Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Merck
Dow
AstraZeneca
Harvard Business School
Farmers Insurance
UBS
Chubb
US Army
Teva

Generated: October 20, 2017

DrugPatentWatch Database Preview

Patents Expiring in February 2020

« Back to Dashboard
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-002Dec 22, 2000ABRXYesYes► Subscribe► SubscribeY
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 2000ABRXYesNo► Subscribe► SubscribeY
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYesYes► Subscribe► SubscribeY TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 2011RXYesYes► Subscribe► SubscribeY
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes► Subscribe► SubscribeY
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-006Apr 23, 2015RXYesYes► Subscribe► SubscribeYY TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-005Apr 23, 2015RXYesNo► Subscribe► SubscribeYY TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► SubscribeYY TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-003Dec 21, 2012RXYesNo► Subscribe► SubscribeYY TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Aegerion
JUXTAPID
lomitapide mesylate
CAPSULE;ORAL203858-002Dec 21, 2012RXYesNo► Subscribe► SubscribeYY TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Argus Health
Johnson and Johnson
Julphar
Healthtrust
Harvard Business School
QuintilesIMS
Chinese Patent Office
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot